What is Medeia?
Medeia Inc. is a prominent player in the health technology sector, focusing on the manufacture and distribution of advanced Neuro Diagnostic and Heart Rate Variability products. The company provides sophisticated biometrical software and hardware solutions designed for monitoring physiological data. Their product portfolio includes cutting-edge systems for neurocognitive assessments, such as the BrainView NeuralScan and EEG devices, alongside cardiovascular monitoring tools like the VitalScan series. Established in 1992, Medeia targets medical professionals across neurology, cardiology, and primary care, aiming to revolutionize patient health evaluation and disease detection through clinician-designed innovations.
How much funding has Medeia raised?
Medeia has raised a total of $1.6M across 2 funding rounds:
Other Financing Round
$1.5M
Debt
$150K
Other Financing Round (2007): $1.5M with participation from Brook Venture Partners
Debt (2020): $150K led by PPP
Key Investors in Medeia
Brook Venture Partners
Brook Venture Partners, now 424 Capital, is a venture capital firm focused on providing capital to expansion-stage businesses, particularly in technology. They act as hands-on partners, actively engaging in corporate development to foster market leaders and offering CFO services and corporate development support.
What's next for Medeia?
The recent major strategic investment signals a pivotal phase for Medeia, likely enabling accelerated product development, market expansion, and enhanced research initiatives. This capital infusion is expected to bolster the company's capabilities in providing advanced biometrical software and hardware, further solidifying its position in the neuro diagnostics and cardiovascular monitoring markets. Medeia's commitment to innovation, driven by clinician insights, positions it for sustained growth and leadership in the health tech industry.
See full Medeia company page
